Die Fundamentaldaten des Unternehmens sind relativ gesund. Seine Bewertung wird als unterbewertet angesehen,und die institutionelle Anerkennung ist sehr hoch. In den letzten 30 Tagen haben mehrere Analysten die Aktie mit einer bewertet. Trotz einer sehr schwachen Entwicklung des Aktienmarktes zeigt das Unternehmen starke Fundamentaldaten. Der Aktienkurs bewegt sich seitwärts zwischen den Unterstützungs- und Widerstandsniveaus, was ihn für schwankungsorientiertes Trading geeignet macht.
Aktienbewertung
Zugehörige Informationen
Branchenrang
120 / 175
Gesamtwertung
454 / 4720
Branche
Pharmazeutika
Widerstand & Unterstützung
Keine Daten
Radar Chart
Aktueller Preis
Vorher
Analysten-Ziel
Basierend auf insgesamt
0
Analysten
--
Aktuelles Rating
3.000
Kursziel
+511.87%
Aufwärtspotenzial
Hinweis: Analystenbewertungen und Kursziele werden von LSEG ausschließlich zu Informationszwecken bereitgestellt und stellen keine Anlageberatung dar.
Unternehmens-Highlights
HöhepunkteRisiko
Cosmos Health Inc. is a global healthcare company. The Company owns a portfolio of pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe and C-Sept. Through its subsidiary, Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It distributes a line of pharmaceuticals and Para pharmaceuticals, including branded generics and over the counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It is also engaged in the research and development (R&D) of patented nutraceuticals and specialized root extracts as well as in the R&D of complex generics and OTC products. It offers Cloudscreen, a multimodal platform specialized in drug repurposing, a process of uncovering new target proteins. It is also specialized in the storage and distribution of pharmaceutical and Para pharmaceutical goods.
Cosmos Health Inc. is a global healthcare company. The Company owns a portfolio of pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe and C-Sept. Through its subsidiary, Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It distributes a line of pharmaceuticals and Para pharmaceuticals, including branded generics and over the counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It is also engaged in the research and development (R&D) of patented nutraceuticals and specialized root extracts as well as in the R&D of complex generics and OTC products. It offers Cloudscreen, a multimodal platform specialized in drug repurposing, a process of uncovering new target proteins. It is also specialized in the storage and distribution of pharmaceutical and Para pharmaceutical goods.